Temozolomide treatment of a malignant pheochromocytoma and an unresectable MAX-related paraganglioma

Research output: Contribution to journalArticlepeer-review


Pheochromocytomas (PCCs) and paragangliomas (PGLs) are neuroendocrine tumors with a strong genetic background. The mainstay of treatment for PCC/PGLs is surgery. However, for unresectable lesions, no curative treatment is currently available. Temozolomide (TMZ) has been shown to determine radiological and biochemical response in malignant PCC/PGLs. We report two cases of PCC/PGLs treated with TMZ. Case 1 is a 51-year-old man with local and distant recurrence (liver and bone metastases) of right adrenal PCC. Case 2 is a 54-year-old woman with a PCC/PGL syndrome caused by a mutation in MAX gene (c.171 + 1G > A), operated on for bilateral adrenal PCC and presenting with a large unresectable abdominal PGL. Both patients presented hypertension due to catecholamine hypersecretion. TMZ determined radiological response according to RECIST criteria, reduction of urinary catecholamine levels, and controlled hypertension in both patients. Furthermore, the current study demonstrates, for the first time, that MAX-related PGLs are responsive to TMZ.

Original languageEnglish
Pages (from-to)102-105
Number of pages4
JournalAnti-Cancer Drugs
Issue number1
Publication statusPublished - Jan 1 2018


  • Abdominal paraganglioma
  • Malignant pheochromocytoma
  • MAX gene
  • Metanephrine
  • Normetanephrine
  • Radiological response
  • Temozolomide

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Cancer Research

Fingerprint Dive into the research topics of 'Temozolomide treatment of a malignant pheochromocytoma and an unresectable MAX-related paraganglioma'. Together they form a unique fingerprint.

Cite this